Skip to main content
Advertisement

Main menu

  • Home
  • Articles
    • Current Issue
    • Fast Forward
    • Latest Articles
    • Archive
  • Information
    • Instructions to Authors
    • Submit a Manuscript
    • FAQs
    • For Subscribers
    • Terms & Conditions of Use
    • Permissions
  • Editorial Board
  • Alerts
    • Alerts
    • RSS Feeds
  • Virtual Issues
  • Feedback
  • Other Publications
    • Drug Metabolism and Disposition
    • Journal of Pharmacology and Experimental Therapeutics
    • Molecular Pharmacology
    • Pharmacological Reviews
    • Pharmacology Research & Perspectives
    • ASPET

User menu

  • My alerts
  • Log in
  • My Cart

Search

  • Advanced search
Molecular Pharmacology
  • Other Publications
    • Drug Metabolism and Disposition
    • Journal of Pharmacology and Experimental Therapeutics
    • Molecular Pharmacology
    • Pharmacological Reviews
    • Pharmacology Research & Perspectives
    • ASPET
  • My alerts
  • Log in
  • My Cart
Molecular Pharmacology

Advanced Search

  • Home
  • Articles
    • Current Issue
    • Fast Forward
    • Latest Articles
    • Archive
  • Information
    • Instructions to Authors
    • Submit a Manuscript
    • FAQs
    • For Subscribers
    • Terms & Conditions of Use
    • Permissions
  • Editorial Board
  • Alerts
    • Alerts
    • RSS Feeds
  • Virtual Issues
  • Feedback
  • Visit molpharm on Facebook
  • Follow molpharm on Twitter
  • Follow molpharm on LinkedIn
Research ArticleArticle

Investigating Metabotropic Glutamate Receptor 5 Allosteric Modulator Cooperativity, Affinity, and Agonism: Enriching Structure-Function Studies and Structure-Activity Relationships

Karen J. Gregory, Meredith J. Noetzel, Jerri M. Rook, Paige N. Vinson, Shaun R. Stauffer, Alice L. Rodriguez, Kyle A. Emmitte, Ya Zhou, Aspen C. Chun, Andrew S. Felts, Brian A. Chauder, Craig W. Lindsley, Colleen M. Niswender and P. Jeffrey Conn
Molecular Pharmacology November 2012, 82 (5) 860-875; DOI: https://doi.org/10.1124/mol.112.080531
Karen J. Gregory
Vanderbilt Center for Neuroscience Drug Discovery (K.J.G., M.J.N., J.M.R., P.N.V., S.R.S., A.L.R., K.A.E., Y.Z., A.C.C., A.S.F., B.A.C., C.W.L., C.M.N., P.J.C.) and Departments of Pharmacology (K.J.G., M.J.N., J.M.R., P.N.V., S.R.S., A.L.R., K.A.E., Y.Z., A.C.C., A.S.F., B.A.C., C.W.L., C.M.N., P.J.C.) and Chemistry (K.A.E., C.W.L.), Vanderbilt University Medical Center, Nashville, Tennessee; and Drug Discovery Biology, Monash Institute of Pharmaceutical Sciences, Monash University, Parkville, Australia (K.J.G.)
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Meredith J. Noetzel
Vanderbilt Center for Neuroscience Drug Discovery (K.J.G., M.J.N., J.M.R., P.N.V., S.R.S., A.L.R., K.A.E., Y.Z., A.C.C., A.S.F., B.A.C., C.W.L., C.M.N., P.J.C.) and Departments of Pharmacology (K.J.G., M.J.N., J.M.R., P.N.V., S.R.S., A.L.R., K.A.E., Y.Z., A.C.C., A.S.F., B.A.C., C.W.L., C.M.N., P.J.C.) and Chemistry (K.A.E., C.W.L.), Vanderbilt University Medical Center, Nashville, Tennessee; and Drug Discovery Biology, Monash Institute of Pharmaceutical Sciences, Monash University, Parkville, Australia (K.J.G.)
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Jerri M. Rook
Vanderbilt Center for Neuroscience Drug Discovery (K.J.G., M.J.N., J.M.R., P.N.V., S.R.S., A.L.R., K.A.E., Y.Z., A.C.C., A.S.F., B.A.C., C.W.L., C.M.N., P.J.C.) and Departments of Pharmacology (K.J.G., M.J.N., J.M.R., P.N.V., S.R.S., A.L.R., K.A.E., Y.Z., A.C.C., A.S.F., B.A.C., C.W.L., C.M.N., P.J.C.) and Chemistry (K.A.E., C.W.L.), Vanderbilt University Medical Center, Nashville, Tennessee; and Drug Discovery Biology, Monash Institute of Pharmaceutical Sciences, Monash University, Parkville, Australia (K.J.G.)
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Paige N. Vinson
Vanderbilt Center for Neuroscience Drug Discovery (K.J.G., M.J.N., J.M.R., P.N.V., S.R.S., A.L.R., K.A.E., Y.Z., A.C.C., A.S.F., B.A.C., C.W.L., C.M.N., P.J.C.) and Departments of Pharmacology (K.J.G., M.J.N., J.M.R., P.N.V., S.R.S., A.L.R., K.A.E., Y.Z., A.C.C., A.S.F., B.A.C., C.W.L., C.M.N., P.J.C.) and Chemistry (K.A.E., C.W.L.), Vanderbilt University Medical Center, Nashville, Tennessee; and Drug Discovery Biology, Monash Institute of Pharmaceutical Sciences, Monash University, Parkville, Australia (K.J.G.)
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Shaun R. Stauffer
Vanderbilt Center for Neuroscience Drug Discovery (K.J.G., M.J.N., J.M.R., P.N.V., S.R.S., A.L.R., K.A.E., Y.Z., A.C.C., A.S.F., B.A.C., C.W.L., C.M.N., P.J.C.) and Departments of Pharmacology (K.J.G., M.J.N., J.M.R., P.N.V., S.R.S., A.L.R., K.A.E., Y.Z., A.C.C., A.S.F., B.A.C., C.W.L., C.M.N., P.J.C.) and Chemistry (K.A.E., C.W.L.), Vanderbilt University Medical Center, Nashville, Tennessee; and Drug Discovery Biology, Monash Institute of Pharmaceutical Sciences, Monash University, Parkville, Australia (K.J.G.)
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Alice L. Rodriguez
Vanderbilt Center for Neuroscience Drug Discovery (K.J.G., M.J.N., J.M.R., P.N.V., S.R.S., A.L.R., K.A.E., Y.Z., A.C.C., A.S.F., B.A.C., C.W.L., C.M.N., P.J.C.) and Departments of Pharmacology (K.J.G., M.J.N., J.M.R., P.N.V., S.R.S., A.L.R., K.A.E., Y.Z., A.C.C., A.S.F., B.A.C., C.W.L., C.M.N., P.J.C.) and Chemistry (K.A.E., C.W.L.), Vanderbilt University Medical Center, Nashville, Tennessee; and Drug Discovery Biology, Monash Institute of Pharmaceutical Sciences, Monash University, Parkville, Australia (K.J.G.)
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Kyle A. Emmitte
Vanderbilt Center for Neuroscience Drug Discovery (K.J.G., M.J.N., J.M.R., P.N.V., S.R.S., A.L.R., K.A.E., Y.Z., A.C.C., A.S.F., B.A.C., C.W.L., C.M.N., P.J.C.) and Departments of Pharmacology (K.J.G., M.J.N., J.M.R., P.N.V., S.R.S., A.L.R., K.A.E., Y.Z., A.C.C., A.S.F., B.A.C., C.W.L., C.M.N., P.J.C.) and Chemistry (K.A.E., C.W.L.), Vanderbilt University Medical Center, Nashville, Tennessee; and Drug Discovery Biology, Monash Institute of Pharmaceutical Sciences, Monash University, Parkville, Australia (K.J.G.)
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Ya Zhou
Vanderbilt Center for Neuroscience Drug Discovery (K.J.G., M.J.N., J.M.R., P.N.V., S.R.S., A.L.R., K.A.E., Y.Z., A.C.C., A.S.F., B.A.C., C.W.L., C.M.N., P.J.C.) and Departments of Pharmacology (K.J.G., M.J.N., J.M.R., P.N.V., S.R.S., A.L.R., K.A.E., Y.Z., A.C.C., A.S.F., B.A.C., C.W.L., C.M.N., P.J.C.) and Chemistry (K.A.E., C.W.L.), Vanderbilt University Medical Center, Nashville, Tennessee; and Drug Discovery Biology, Monash Institute of Pharmaceutical Sciences, Monash University, Parkville, Australia (K.J.G.)
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Aspen C. Chun
Vanderbilt Center for Neuroscience Drug Discovery (K.J.G., M.J.N., J.M.R., P.N.V., S.R.S., A.L.R., K.A.E., Y.Z., A.C.C., A.S.F., B.A.C., C.W.L., C.M.N., P.J.C.) and Departments of Pharmacology (K.J.G., M.J.N., J.M.R., P.N.V., S.R.S., A.L.R., K.A.E., Y.Z., A.C.C., A.S.F., B.A.C., C.W.L., C.M.N., P.J.C.) and Chemistry (K.A.E., C.W.L.), Vanderbilt University Medical Center, Nashville, Tennessee; and Drug Discovery Biology, Monash Institute of Pharmaceutical Sciences, Monash University, Parkville, Australia (K.J.G.)
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Andrew S. Felts
Vanderbilt Center for Neuroscience Drug Discovery (K.J.G., M.J.N., J.M.R., P.N.V., S.R.S., A.L.R., K.A.E., Y.Z., A.C.C., A.S.F., B.A.C., C.W.L., C.M.N., P.J.C.) and Departments of Pharmacology (K.J.G., M.J.N., J.M.R., P.N.V., S.R.S., A.L.R., K.A.E., Y.Z., A.C.C., A.S.F., B.A.C., C.W.L., C.M.N., P.J.C.) and Chemistry (K.A.E., C.W.L.), Vanderbilt University Medical Center, Nashville, Tennessee; and Drug Discovery Biology, Monash Institute of Pharmaceutical Sciences, Monash University, Parkville, Australia (K.J.G.)
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Brian A. Chauder
Vanderbilt Center for Neuroscience Drug Discovery (K.J.G., M.J.N., J.M.R., P.N.V., S.R.S., A.L.R., K.A.E., Y.Z., A.C.C., A.S.F., B.A.C., C.W.L., C.M.N., P.J.C.) and Departments of Pharmacology (K.J.G., M.J.N., J.M.R., P.N.V., S.R.S., A.L.R., K.A.E., Y.Z., A.C.C., A.S.F., B.A.C., C.W.L., C.M.N., P.J.C.) and Chemistry (K.A.E., C.W.L.), Vanderbilt University Medical Center, Nashville, Tennessee; and Drug Discovery Biology, Monash Institute of Pharmaceutical Sciences, Monash University, Parkville, Australia (K.J.G.)
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Craig W. Lindsley
Vanderbilt Center for Neuroscience Drug Discovery (K.J.G., M.J.N., J.M.R., P.N.V., S.R.S., A.L.R., K.A.E., Y.Z., A.C.C., A.S.F., B.A.C., C.W.L., C.M.N., P.J.C.) and Departments of Pharmacology (K.J.G., M.J.N., J.M.R., P.N.V., S.R.S., A.L.R., K.A.E., Y.Z., A.C.C., A.S.F., B.A.C., C.W.L., C.M.N., P.J.C.) and Chemistry (K.A.E., C.W.L.), Vanderbilt University Medical Center, Nashville, Tennessee; and Drug Discovery Biology, Monash Institute of Pharmaceutical Sciences, Monash University, Parkville, Australia (K.J.G.)
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Colleen M. Niswender
Vanderbilt Center for Neuroscience Drug Discovery (K.J.G., M.J.N., J.M.R., P.N.V., S.R.S., A.L.R., K.A.E., Y.Z., A.C.C., A.S.F., B.A.C., C.W.L., C.M.N., P.J.C.) and Departments of Pharmacology (K.J.G., M.J.N., J.M.R., P.N.V., S.R.S., A.L.R., K.A.E., Y.Z., A.C.C., A.S.F., B.A.C., C.W.L., C.M.N., P.J.C.) and Chemistry (K.A.E., C.W.L.), Vanderbilt University Medical Center, Nashville, Tennessee; and Drug Discovery Biology, Monash Institute of Pharmaceutical Sciences, Monash University, Parkville, Australia (K.J.G.)
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
P. Jeffrey Conn
Vanderbilt Center for Neuroscience Drug Discovery (K.J.G., M.J.N., J.M.R., P.N.V., S.R.S., A.L.R., K.A.E., Y.Z., A.C.C., A.S.F., B.A.C., C.W.L., C.M.N., P.J.C.) and Departments of Pharmacology (K.J.G., M.J.N., J.M.R., P.N.V., S.R.S., A.L.R., K.A.E., Y.Z., A.C.C., A.S.F., B.A.C., C.W.L., C.M.N., P.J.C.) and Chemistry (K.A.E., C.W.L.), Vanderbilt University Medical Center, Nashville, Tennessee; and Drug Discovery Biology, Monash Institute of Pharmaceutical Sciences, Monash University, Parkville, Australia (K.J.G.)
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • Article
  • Figures & Data
  • Info & Metrics
  • eLetters
  • PDF + SI
  • PDF
Loading

Abstract

Drug discovery programs increasingly are focusing on allosteric modulators as a means to modify the activity of G protein-coupled receptor (GPCR) targets. Allosteric binding sites are topographically distinct from the endogenous ligand (orthosteric) binding site, which allows for co-occupation of a single receptor with the endogenous ligand and an allosteric modulator that can alter receptor pharmacological characteristics. Negative allosteric modulators (NAMs) inhibit and positive allosteric modulators (PAMs) enhance the affinity and/or efficacy of orthosteric agonists. Established approaches for estimation of affinity and efficacy values for orthosteric ligands are not appropriate for allosteric modulators, and this presents challenges for fully understanding the actions of novel modulators of GPCRs. Metabotropic glutamate receptor 5 (mGlu5) is a family C GPCR for which a large array of allosteric modulators have been identified. We took advantage of the many tools for probing allosteric sites on mGlu5 to validate an operational model of allosterism that allows quantitative estimation of modulator affinity and cooperativity values. Affinity estimates derived from functional assays fit well with affinities measured in radioligand binding experiments for both PAMs and NAMs with diverse chemical scaffolds and varying degrees of cooperativity. We observed modulation bias for PAMs when we compared mGlu5-mediated Ca2+ mobilization and extracellular signal-regulated kinase 1/2 phosphorylation data. Furthermore, we used this model to quantify the effects of mutations that reduce binding or potentiation by PAMs. This model can be applied to PAM and NAM potency curves in combination with maximal fold-shift data to derive reliable estimates of modulator affinities.

Footnotes

  • ↵Embedded Image The online version of this article (available at http://molpharm.aspetjournals.org) contains supplemental material.

  • This work was supported by the National Institutes of Health National Institute of Mental Health [Grant 2R01-MH062646-13]; the National Institutes of Health National Institute of Neurological Disorders and Stroke [Grant 2R01-NS031373-16A2]; the National Institutes of Health National Institute of Drug Abuse [Grant 1R01-DA023947]; the Molecular Libraries Probe Production Centers Network [Grants 5U54-MH84659-03, 5U54-MH84659-03S1]; a National Institutes of Health National Institute of Neurological Disorders and Stroke National Research Service Award [Grant F32-NS071746] (to M.J.N.); a National Institutes of Health National Institute of Mental Health National Research Service Award [Grant F32-MH088234-02] (to J.M.R.); a National Alliance for Research on Schizophrenia and Depression Maltz Investigator Award (to K.J.G.); an American Australian Association Merck Foundation fellowship (to K.J.G.); and a National Health and Medical Research Council (Australia) overseas biomedical postdoctoral training fellowship (to K.J.G.). P.J.C. is a consultant for Seaside Therapeutics and receives research support from Seaside Therapeutics and Johnson and Johnson/Janssen Pharmaceutica.

  • Article, publication date, and citation information can be found at http://molpharm.aspetjournals.org.

    http://dx.doi.org/10.1124/mol.112.080531.

  • ABBREVIATIONS:

    mGlu
    metabotropic glutamate receptor
    methoxy-PEPy
    3-methoxy-5-(pyridin-2-ylethynyl)pyridine
    CDPPB
    3-cyano-N-(1,3-diphenyl-1H-pyrazol-5-yl)benzamide
    CPPHA
    N-{4-chloro-2-[(1,3-dioxo-1,3-dihydro-2H-isoindol-2-yl)methyl]phenyl}-2-hydroxybenzamide
    DMEM
    Dulbecco's modified Eagle's medium
    ERK
    extracellular signal-regulated kinase
    GPCR
    G protein-coupled receptor
    HEK
    human embryonic kidney
    M-5MPEP
    2-[2-(3-methoxyphenyl)ethynyl]-5-methylpyridine
    MPEP
    2-methyl-6-(phenylethynyl)pyridine
    MTEP
    3-[(2-methyl-1,3-thiazol-4-yl)ethynyl]pyridine
    NAM
    negative allosteric modulator
    PAM
    positive allosteric modulator
    SAR
    structure-activity relationship
    SIB-1757
    6-methyl-2-(phenylazo)-3-pyridinol
    SIB-1893
    (E)-2-methyl-6-(2-phenylethenyl)pyridine
    VU0092273
    1-{[4-(2-phenylethynyl)phenyl]carbonyl}piperidin-4-ol
    VU0285683
    3-fluoro-5-[3-(pyridin-2-yl)-1,2,4-oxadiazol-5-yl]benzonitrile
    VU0357121
    4-butoxy-N-(2,4-difluorophenyl)benzamide
    VU0360172
    N-cyclobutyl-6-[(3-fluorophenyl)ethynyl]nicotinamide hydrochloride
    VU0364289
    2-{4-[2-(benzyloxy)acetyl]piperazin-1-yl}benzonitrile
    VU0366248
    N-(3-chloro-2-fluorophenyl)-3-cyano-5-fluorobenzamide
    VU0366249
    N-(3-chloro-4-fluorophenyl)-3-cyano-5-fluorobenzamide
    VU0405386
    N-tert-butyl-5-[(3-fluorophenyl)ethynyl]picolinamide
    VU0405398
    [5-[(3-fluorophenyl)ethynyl]pyridin-2-yl](3-hydroxyazetidin-1-yl)methanone
    VU0415051
    N-tert-butyl-6-[2-(3-fluorophenyl)ethynyl]pyridine-3-carboxamide
    VU0366058
    2-(1,3-benzoxazol-2-ylamino)-4-(4-fluorophenyl)pyrimidine-5-carbonitrile
    VU29
    4-nitro-N-(1,3-diphenyl-1H-pyrazol-5-yl)benzamide.

  • Received June 9, 2012.
  • Accepted August 2, 2012.
  • Copyright © 2012 The American Society for Pharmacology and Experimental Therapeutics
View Full Text

MolPharm articles become freely available 12 months after publication, and remain freely available for 5 years. 

Non-open access articles that fall outside this five year window are available only to institutional subscribers and current ASPET members, or through the article purchase feature at the bottom of the page. 

 

  • Click here for information on institutional subscriptions.
  • Click here for information on individual ASPET membership.

 

Log in using your username and password

Forgot your user name or password?

Purchase access

You may purchase access to this article. This will require you to create an account if you don't already have one.
PreviousNext
Back to top

In this issue

Molecular Pharmacology: 82 (5)
Molecular Pharmacology
Vol. 82, Issue 5
1 Nov 2012
  • Table of Contents
  • Table of Contents (PDF)
  • About the Cover
  • Index by author
  • Editorial Board (PDF)
  • Front Matter (PDF)
Download PDF
Article Alerts
Sign In to Email Alerts with your Email Address
Email Article

Thank you for sharing this Molecular Pharmacology article.

NOTE: We request your email address only to inform the recipient that it was you who recommended this article, and that it is not junk mail. We do not retain these email addresses.

Enter multiple addresses on separate lines or separate them with commas.
Investigating Metabotropic Glutamate Receptor 5 Allosteric Modulator Cooperativity, Affinity, and Agonism: Enriching Structure-Function Studies and Structure-Activity Relationships
(Your Name) has forwarded a page to you from Molecular Pharmacology
(Your Name) thought you would be interested in this article in Molecular Pharmacology.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Citation Tools
Research ArticleArticle

Delineating mGlu5 Modulator Affinity and Cooperativity

Karen J. Gregory, Meredith J. Noetzel, Jerri M. Rook, Paige N. Vinson, Shaun R. Stauffer, Alice L. Rodriguez, Kyle A. Emmitte, Ya Zhou, Aspen C. Chun, Andrew S. Felts, Brian A. Chauder, Craig W. Lindsley, Colleen M. Niswender and P. Jeffrey Conn
Molecular Pharmacology November 1, 2012, 82 (5) 860-875; DOI: https://doi.org/10.1124/mol.112.080531

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
Share
Research ArticleArticle

Delineating mGlu5 Modulator Affinity and Cooperativity

Karen J. Gregory, Meredith J. Noetzel, Jerri M. Rook, Paige N. Vinson, Shaun R. Stauffer, Alice L. Rodriguez, Kyle A. Emmitte, Ya Zhou, Aspen C. Chun, Andrew S. Felts, Brian A. Chauder, Craig W. Lindsley, Colleen M. Niswender and P. Jeffrey Conn
Molecular Pharmacology November 1, 2012, 82 (5) 860-875; DOI: https://doi.org/10.1124/mol.112.080531
del.icio.us logo Digg logo Reddit logo Twitter logo CiteULike logo Facebook logo Google logo Mendeley logo
  • Tweet Widget
  • Facebook Like
  • Google Plus One

Jump to section

  • Article
    • Abstract
    • Introduction
    • Materials and Methods
    • Results
    • Discussion
    • Authorship Contributions
    • Acknowledgments
    • Footnotes
    • References
  • Figures & Data
  • Info & Metrics
  • eLetters
  • PDF + SI
  • PDF

Related Articles

Cited By...

More in this TOC Section

  • 6-Methylflavone Blocks Bitterness of Tenofovir
  • Positive Allosteric Modulation of the mGlu5 Receptor
  • Correction of mutant CNGA3 channel trafficking defect
Show more Articles

Similar Articles

Advertisement
  • Home
  • Alerts
Facebook   Twitter   LinkedIn   RSS

Navigate

  • Current Issue
  • Fast Forward by date
  • Fast Forward by section
  • Latest Articles
  • Archive
  • Search for Articles
  • Feedback
  • ASPET

More Information

  • About Molecular Pharmacology
  • Editorial Board
  • Instructions to Authors
  • Submit a Manuscript
  • Customized Alerts
  • RSS Feeds
  • Subscriptions
  • Permissions
  • Terms & Conditions of Use

ASPET's Other Journals

  • Drug Metabolism and Disposition
  • Journal of Pharmacology and Experimental Therapeutics
  • Pharmacological Reviews
  • Pharmacology Research & Perspectives
ISSN 1521-0111 (Online)

Copyright © 2021 by the American Society for Pharmacology and Experimental Therapeutics